Compare · AZN vs CORT
AZN vs CORT
Side-by-side comparison of AstraZeneca PLC (AZN) and Corcept Therapeutics Incorporated (CORT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AZN and CORT operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- AZN is the larger of the two at $576.71B, about 74.0x CORT ($7.80B).
- CORT has been more active in the news (23 items in the past 4 weeks vs 21 for AZN).
- AZN has more recent analyst coverage (25 ratings vs 15 for CORT).
- Company
- AstraZeneca PLC
- Corcept Therapeutics Incorporated
- Price
- $186.00+2.32%
- $72.77-2.84%
- Market cap
- $576.71B
- $7.80B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2026
- 2004
- News (4w)
- 21
- 23
- Recent ratings
- 25
- 15
AstraZeneca PLC
AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastroenterology worldwide. The company's marketed products include Tagrisso, Lynparza, Imfinzi, Enhertu, Koselugo, Lumoxiti, Equidacent, Zoladex, Faslodex, Iressa, Arimidex, Casodex/Cosudex, and others for oncology diseases; Onglyza, Bydureon, Lokelma, Byetta, Qtern, Symlin, and others for cardiovascular, renal, and metabolism diseases; and Symbicort, Pulmicort, Fasenra, Daliresp/Daxas, Duaklir, Tudorza/Eklira, Bevespi, Breztri, Anifrolumab, and others for respiratory and immunology diseases. It also offers other medicines and COVID-19 products, including Synagis, Fluenz Tetra/FluMist Quadrivalent, Seroquel IR/Seroquel XR, Vimovo, Movantik/Moventig, Nexium, Losec/Prilosec, and COVID-19 Vaccine AstraZeneca. The company serves primary care and specialty care physicians through distributors and local representative offices. It has a collaboration agreement with Daiichi Sankyo to develop and commercialize DS-1062 for the treatment of trophoblast cell-surface antigen 2 (TROP2) tumor; AliveCor, Inc. to develop non-invasive potassium monitoring solutions; Massachusetts General Hospital to accelerate digital health solutions; Sanguina on smartphone application study for hemoglobin management in patients with anemia of chronic kidney disease; Alchemab to enhance prostate cancer research; and Proteros biostructures GmbH to discover and develop novel small molecules for the treatment of various types of cancer. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Corcept Therapeutics Incorporated
Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and psychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. It is developing relacorilant to treat patients with Cushing's syndrome; and nab-paclitaxel in combination with relacorilant, which has completed Phase II clinical trial to treat patients with serous ovarian tumors, as well as in Phase III clinical trial for the treatment of solid tumors. The company is also developing selective cortisol modulator combined with Xtandi that is in open label dose finding trial to treat patients with metastatic castration-resistant prostate cancer; selective cortisol modulator for the treatment of antipsychotic-induced weight gain; and FKBP5 gene expression assays. Corcept Therapeutics Incorporated was founded in 1998 and is headquartered in Menlo Park, California.
Latest AZN
- NYSE Content Update: AstraZeneca Celebrates Largest Transfer in NYSE History
- Camizestrant Combination Delayed Time to First Progression by 55% and to Second Progression by 37% in Patients With Advanced HR-positive Breast Cancer With an Emergent ESR1 Tumor Mutation in SERENA-6 Trial
- SEC Form 6-K filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
- IMFINZI® (durvalumab) plus IMJUDO® (tremelimumab-actl) combined with lenvatinib and TACE reduced the risk of disease progression or death by 30% in embolization-eligible unresectable liver cancer in EMERALD-3 Phase III trial
- SEC Form 6-K filed by AstraZeneca PLC
- IMFINZI® (durvalumab) approved in the US in first and only immunotherapy combination for patients with BCG-naïve, high-risk non-muscle-invasive bladder cancer
- SEC Form 25-NSE filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
Latest CORT
- Corcept Presents New Data at ADA: Improved Outcomes in Patients Receiving a GLP-1 with Difficult-to-Control Type 2 Diabetes and Hypercortisolism Treated with Korlym®
- Chief Development Officer Guyer William exercised 20,000 shares at a strike of $21.65 and sold $1,412,000 worth of shares (20,000 units at $70.60) as part of a pre-agreed trading plan (SEC Form 4)
- Officer Lyon Joseph Douglas was granted 1,074 shares and covered exercise/tax liability with 269 shares, increasing direct ownership by 13% to 7,035 units (SEC Form 4) (tax liability)
- Chief Development Officer Guyer William was granted 1,754 shares, increasing direct ownership by 79% to 3,985 units (SEC Form 4)
- Officer Maduck Sean exercised 25,000 shares at a strike of $8.27, sold $1,755,183 worth of shares (25,000 units at $70.21) as part of a pre-agreed trading plan, was granted 1,230 shares and covered exercise/tax liability with 452 shares, increasing direct ownership by 9% to 9,755 units (SEC Form 4) (for withholding tax)
- Chief Financial Officer Mokari Atabak exercised 40,000 shares at a strike of $19.26, sold $2,800,004 worth of shares (40,000 units at $70.00) as part of a pre-agreed trading plan, was granted 1,268 shares and covered exercise/tax liability with 395 shares, increasing direct ownership by 6% to 16,130 units (SEC Form 4) (tax withholding)
- Chief Business Officer Robb Gary Charles was granted 1,552 shares and covered exercise/tax liability with 358 shares, increasing direct ownership by 5% to 25,681 units (SEC Form 4) to satisfy tax liability
- SEC Form 8-K filed by Corcept Therapeutics Incorporated
- Chief Executive Officer Belanoff Joseph K gifted 300,000 shares, received a gift of 300,000 shares and sold $895,252 worth of shares (12,837 units at $69.74) as part of a pre-agreed trading plan (SEC Form 4)
- Officer Lyon Joseph Douglas sold $325,000 worth of shares (5,000 units at $65.00), decreasing direct ownership by 45% to 6,230 units (SEC Form 4)